Scotchbond Universal Plus Compared to Scotchbond Universal for Posterior Class I & II Restorations With Filtek Universal
Launched by SOLVENTUM US LLC · Feb 10, 2022
Trial Information
Current as of May 20, 2025
Active, not recruiting
Keywords
ClinConnect Summary
This clinical trial is investigating a new dental adhesive called 3M™ Scotchbond™ Universal Plus Adhesive (SBU+) to see if it works as well as an existing adhesive, Scotchbond™ Universal Adhesive (SBU), for sealing dental fillings in back teeth. The study involves adult participants who need fillings for at least two back teeth that have cavities. One tooth will be treated with the new adhesive, and the other with the standard adhesive, with both receiving the same filling material.
To participate, individuals should be between 18 and 70 years old, in good overall health, and have at least two teeth that require fillings on the chewing surface or between teeth. Participants will need to be available for all study visits and must understand the study procedures. It’s important to note that certain conditions, like pregnancy or specific dental issues, may exclude a person from participating. Those who join the trial will help researchers determine if this new adhesive can improve dental restoration treatments.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. The Subject is between the ages of 18 and 70 years old at time of consent.
- • 2. The Subject requires at least two direct composite restorations for posterior Class I or Class II carious lesions in vital teeth that are asymptomatic and with minimal mobility (\< 1 mm in the buccolingual direction).
- • 3. Study teeth have a minimum buccolingual diameter of the occlusal surface that is at least 1/3 of the distance between the buccal and lingual cusps
- • 4. Teeth selected for Class II restorations need to have an adjacent tooth in a position that will allow for a contact relationship to be established.
- • 5. The Subject is able and willing to sign Informed Consent Form in English without assistance.
- • 6. The Subject is able and willing to be available for all scheduled study visits.
- • 7. The Subject is in good general health (ie, meets ASA Level I or ASA Level II classification criteria).
- • 8. The selected teeth need to have occlusal contact with an antagonistic natural tooth.
- • 9. The Subject has existing radiographic images of the study teeth of current and acceptable diagnostic quality obtained within the previous 12 months.
- Exclusion Criteria:
- • 1. The Subject has a history of adverse reaction to any materials used in this study.
- • 2. The Subject is pregnant or breast feeding at the time of screening.
- • 3. The Subject has fewer than 20 teeth.
- • 4. The Subject is taking part in or planned to be enrolled in an evaluation of other restorative materials at any time during the study.
- • 5. The Subject has advanced periodontal disease (ie, Grace \& Smales Mobility Index grade ≥ 2) that involve the study teeth.
- • 6. The Subject had orthodontic appliance treatment within the previous 3 months.
- • 7. The Subject has pronounced enamel wear facets, indicating severe, on-going bruxism.
- • 8. The Subject has severe xerostomia.
- • 9. The study tooth has a history of or existing, prolonged tooth hypersensitivity.
- • 10. The study tooth is an abutment for fixed or removable prostheses.
- • 11. The study tooth has a fracture or is visibly cracked such that it may impact the longevity of the tooth.
- • 12. The carious lesion is stage RC5 or RC6 of the ICDAS radiographic scoring system.
- • 13. The Subject is unable to understand study procedures or provide consent in English.
- • 14. The Subject is an employee or student of the study investigator(s).
- Intraoperative Exclusion Criteria:
- • 1) The Subject has pulp exposure of either study tooth during the restoration procedure.
About Solventum Us Llc
Solventum US LLC is a dedicated clinical trial sponsor focused on advancing innovative therapeutic solutions through rigorous research and development. With a commitment to improving patient outcomes, the company specializes in conducting high-quality clinical trials across various therapeutic areas, leveraging cutting-edge technology and methodologies. Solventum US LLC collaborates with leading healthcare professionals and institutions to ensure the highest standards of safety and efficacy in its studies, ultimately aiming to bring transformative treatments to market. Through its strategic approach and emphasis on scientific integrity, Solventum US LLC plays a vital role in the evolution of modern medicine.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Minneapolis, Minnesota, United States
Patients applied
Trial Officials
Jorge Perdigao, DMD, MS, PhD
Principal Investigator
University of Minnesota
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials